ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NSRX vs JNJ // REVENUE GROWTH (YOY)

Nasus Pharma Ltd. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NSRX 0 — JNJ 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NSRX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NSRX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -13.20% 2.97% -16.17 JNJ /fcf-yield <GO>
Operating Margin -0.40% 34.70% -35.10 JNJ /operating-margins <GO>
Net Profit Margin -0.50% 28.50% -29.00 JNJ /net-margins <GO>
Revenue Growth (YoY) ACTIVE — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.4 62.1 -18.70 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $37.4M $662.49B -$662.45B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NSRX REV JNJ REV NSRX GROSS % JNJ GROSS % NSRX FCF JNJ FCF
FY 2025 $1.24B $94.19B — 67.9% -$4.9M $19.70B
FY 2024 $0 $88.82B — 69.1% -$665.0K $19.84B
FY 2023 $0 $85.16B — — -$1.0M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NSRX // BETA —
JNJ // BETA 1.08